Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
This article was originally published in The Pink Sheet Daily
Executive Summary
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.
You may also be interested in...
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.